varicella zoster virus vzv through mrna technology clinical trial intelligence

A Randomized, Blinded and Positive-Control Phase I Clinical Trial to Evaluate the Immunogenicity and Safety of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

Suzhou Abogen Biosciences Co., Ltd. is advancing its lyophilized herpes zoster mRNA vaccine, ABO1108, targeting adults aged 40 years and older. The vaccine aims to address the significant market need for effective herpes zoster prevention, particularly in aging populations. The competitive landscape includes established vaccines like Shingrix, which may pose a challenge in terms of market penetration. The trial's focus on safety and immunogenicity will be critical for regulatory approval and subsequent market acceptance. Given the aging demographic and rising incidence of herpes zoster, successful outcomes could position ABO1108 favorably within the growing vaccine market, potentially leading to lucrative commercial opportunities.

Matched by target_normalized: Varicella-zoster Virus (VZV) through mRNA technology